NCT07668583 Zoledronic Acid Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready landscape. This focused report examines NCT07668583—EFFICACY AND SAFETY OF ZOLEDRONATE VERSUS PLACEBO ON PAIN AT WEEK 12 IN PEDIATRIC PATIENTS WITH CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS (POMREP)—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why NCT07668583 is a hot trial to watch

Pain is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. NCT07668583 is notable because it evaluates Zoledronic Acid in a Phase 2 design while Change in standardized pain score (0-10 scale) from baseline to week 12, using Visual Analog Scale VAS 0-10/ 0 = no pain ; 10 = worst imaginable pain serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The phase label is only the starting point. Allocation is Randomized, masking is Quadruple, and the intervention model is Parallel Assignment. Planned enrollment of 30 participants across France shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Primary: Change in standardized pain score (0-10 scale) from baseline to week 12, using Visual Analog Scale VAS 0-10/ 0 = no pain ; 10 = worst imaginable pain (week 12)
• Secondary: Change in standardized pain score (0-10 scale) from baseline to week 4,24 \&36, using Visual Analog Scale VAS 0-10/ 0 = no pain ; 10 = worst imaginable pain (Week 4, 24 and 36)
• Secondary: compare the use of NSAIDs, other analgesics and corticosteroids between the two groups during follow-up. (Week 12, 24 and 36)
• Secondary: Clinical manifestations will be assessed by physical examination at baseline and at weeks 12, 24 and 36. The proportion of participants presenting each manifestation (pain on palpation, arthritis, spinal deformity, dermatological manifestations, inflammatory bowel disease, growth impairment and pubertal delay) will be compared between groups. (Week 12, 24 and 36)
• Secondary: compare biological inflammatory markers between the two groups at baseline and follow-up visits. (Week 12, 24 and 36)

Benchmark readouts in the surrounding field

• Superficial parasternal intercostal plane block with ropivacaine versus placebo for opioid exposure after cardiac surgery (EPOCH CardioLink-10): a multicentre, double-blind, randomised trial (Phase 3): Opioid Consumption(72 hour): Difference (LS Mean) = -20.7(95.0% CI, -39.0 to -2.3), P-Value = 0.027; Opioid Consumption(72 hour): Difference (LS Mean) = -20.7(95.0% CI, -39.0 to -2.3), P-Value = 0.027
• A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Once Daily Diclofenac Gel AMZ001 in the Treatment of Pain and Symptoms of Knee Osteoarthritis (Phase 3): Change From Baseline in the WOMAC Pain Sub-score in the Target Knee at Week 2.(Mean) = -19.64 Scores on a scale (95% Confidence Interval, -21.66 to -17.61); Change From Baseline in the WOMAC Pain Sub-score in the Target Knee at Week 2.(Mean) = -21.17 Scores on a scale (95% Confidence Interval, -23.22 to -19.12)
• Comparative Efficacy of Two Different Oral Dosage Forms of Acetaminophen for Post-operative Analgesia in Bariatric Surgery Patients (Phase 2): Pain Control(Mean) = 3.8 Units on a scale (0 to 10) (Standard Deviation, 1.5); Pain Control(Mean) = 3.6 Units on a scale (0 to 10) (Standard Deviation, 1.3)

These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.

Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Zoledronic Acid (Approved; Bone resorption factor x FDPS)

Company & Deal Intelligence context: Assistance Publique des Hôpitaux de Paris SA — France — http://www.aphp.fr

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.

Bottom line

NCT07668583 is a focused lens on Pain development. Its value will be determined by whether Zoledronic Acid can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.